The Experts below are selected from a list of 258 Experts worldwide ranked by ideXlab platform
Angelika Banzhoff - One of the best experts on this subject based on the ideXlab platform.
-
potency requirements of rabies vaccines administered intradermally using the thai red cross regimen investigation of the immunogenicity of serially diluted purified chick Embryo Cell rabies vaccine
Vaccine, 2005Co-Authors: Jiri Beran, Angelika Banzhoff, Karel Honegr, Claudius MalerczykAbstract:To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen.
-
reducing the cost of post exposure rabies prophylaxis efficacy of 0 1 ml pcec rabies vaccine administered intradermally using the thai red cross post exposure regimen in patients severely exposed to laboratory confirmed rabid animals
Vaccine, 2005Co-Authors: Beatriz P Quiambao, Angelika Banzhoff, Rolan D Davis, Efren M Dimaano, Cristina Ambas, Claudius MalerczykAbstract:Purified chick Embryo Cell rabies vaccine (PCECV) administered as 0.1 ml intradermally according to the Thai Red Cross (TRC) regimen could reduce the cost of PEP by up to 84% when compared to the traditional five-dose Essen regimen. To confirm the efficacy of 0.1 ml of PCECV using the TRC regimen, a clinical trial was conducted in 113 patients presenting with category III exposures from confirmed rabid animals at two bite referral centres in the Philippines. Patients were monitored monthly for 1 year after exposure. PCECV was well tolerated, no vaccine-related serious adverse events occurred and all patients were alive 1 year after their initial exposure.
-
purified chick Embryo Cell culture rabies vaccine interchangeability with human diploid Cell culture rabies vaccine and comparison of one versus two dose post exposure booster regimen for previously immunized persons
Vaccine, 2000Co-Authors: Deborah J Briggs, Uwe Nicolay, David W Dreesen, Jean E Chin, Rolan D Davis, Chandra R Gordon, Angelika BanzhoffAbstract:Abstract The equivalence and interchangeability of Purified Chick Embryo Cell Culture Rabies Vaccine (PCECV) to Human Diploid Cell Culture Rabies Vaccine (HDCV) and the immunogenicity of a reduced post-exposure regimen with PCECV was investigated. Statistical analyses revealed no difference ( P ≤0.05) between the geometric mean titers (GMT) on day 49 of subjects that received PCECV or HDCV. In Year 2, subjects were boosted with one or two dose(s) of PCECV. No significant difference ( P ≤0.05) was detected between the GMT of the two groups on days 7 and 365 post-booster. Subjects that received HDCV initially developed an adequate anamnestic response to PCECV. On day 21 post-booster, the GMT of subjects that received two boosters was higher (151.6 IU/ml) than those that received one booster (120.9 IU/ml). However, this difference may not be clinically significant.
-
antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick Embryo Cell vaccine or purified vero Cell rabies vaccine
Bulletin of The World Health Organization, 2000Co-Authors: Deborah J Briggs, Angelika Banzhoff, Uwe Nicolay, S Sirikwin, S Tongswas, Boonyuan Dumavibhat, Chantapong WasiAbstract:Although the introduction of tissue culture vaccines for rabies has dramatically improved the immunogenicity and safety of rabies vaccines, they are often prohibitively expensive for developing countries. To examine whether smaller doses of these vaccines could be used, we tested the safety and immunogenicity of purified chick Embryo Cell vaccine (PCECV) on 211 patients in Thailand with World Health Organization (WHO) category II and III exposures to rabies. The patients presented at two Thai hospitals and were randomized into three groups. Patients in Group 1 received 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90. Group 2 was treated similarly, except that purified Vero Cell rabies vaccine (PVRV) was used instead of PCECV. Group 3 received 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90. After 0, 3, 7, 14, 30 and 90 days serum was collected from the subjects and the geometric mean titres (GMTs) of rabies virus neutralizing antibody determined. After 14 days the GMT of 59 patients vaccinated intradermally with PCECV was equivalent to that of patients who received PVRV. Adverse reactions were more frequent in patients who received vaccines intradermally, indicating the reactions were associated with the route of injection, rather than the vaccine per se. We conclude that PCECV is a safe and highly immunogenic vaccine for postexposure rabies vaccination when administered intradermally in 0.1-ml doses using the two-site method ("2,2,2,0,1,1") recommended by WHO.
Claudius Malerczyk - One of the best experts on this subject based on the ideXlab platform.
-
immunogenicity of simulated pcecv postexposure booster doses 1 3 and 5 years after 2 dose and 3 dose primary rabies vaccination in schoolchildren
Advances in preventive medicine, 2011Co-Authors: Thavatchai Kamoltham, Wiravan Thinyounyong, Pakamatz Khawplod, Phran Phraisuwan, Phana Phongchamnaphai, Gerlind Anders, Claudius MalerczykAbstract:Objectives. To assess the immunogenicity of intradermal (ID) booster doses of Purified Chick Embryo Cell rabies vaccine (PCECV, Rabipur) administered to Thai schoolchildren one, three and five years after a primary ID pre-exposure (PrEP) vaccination series. Methods. In this follow-up study of a randomized, open-label, phase II clinical trial, two simulated post-exposure booster doses of PCECV were administered on days 0 and 3 intradermally to 703 healthy schoolchildren, one, three or five years after primary vaccination with either two or three ID doses of 0.1 mL PCECV. Blood was drawn immediately before and 7, 14 and 365 days after the first booster dose to determine rabies virus neutralizing antibody (RVNA) concentrations. Results. An anamnestic response of approximately 30-fold increase in RVNA concentrations was demonstrated within 14 days after booster. All children (100%) developed adequate RVNA concentrations above 0.5 IU/mL. No vaccine related serious adverse events were seen in any of the vaccinees. Conclusion. ID rabies PrEP with PCECV is safe and immunogenic in schoolchildren and the anamnestic response to a two booster dose vaccination series was found to be adequate one, three, and five years after a two- or three-dose primary PrEP vaccination series.
-
potency requirements of rabies vaccines administered intradermally using the thai red cross regimen investigation of the immunogenicity of serially diluted purified chick Embryo Cell rabies vaccine
Vaccine, 2005Co-Authors: Jiri Beran, Angelika Banzhoff, Karel Honegr, Claudius MalerczykAbstract:To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen.
-
reducing the cost of post exposure rabies prophylaxis efficacy of 0 1 ml pcec rabies vaccine administered intradermally using the thai red cross post exposure regimen in patients severely exposed to laboratory confirmed rabid animals
Vaccine, 2005Co-Authors: Beatriz P Quiambao, Angelika Banzhoff, Rolan D Davis, Efren M Dimaano, Cristina Ambas, Claudius MalerczykAbstract:Purified chick Embryo Cell rabies vaccine (PCECV) administered as 0.1 ml intradermally according to the Thai Red Cross (TRC) regimen could reduce the cost of PEP by up to 84% when compared to the traditional five-dose Essen regimen. To confirm the efficacy of 0.1 ml of PCECV using the TRC regimen, a clinical trial was conducted in 113 patients presenting with category III exposures from confirmed rabid animals at two bite referral centres in the Philippines. Patients were monitored monthly for 1 year after exposure. PCECV was well tolerated, no vaccine-related serious adverse events occurred and all patients were alive 1 year after their initial exposure.
Haradanahalli S Ravish - One of the best experts on this subject based on the ideXlab platform.
-
safety of purified chick Embryo Cell rabies vaccine administered in previously vaccinated animal handlers working in a biological park
International Journal of Advanced Community Medicine, 2019Co-Authors: H S Anwith, Nitu Kumari, M P Ramya, Haradanahalli S RavishAbstract:Background: Wild animal handlers are at continuous risk of exposure to rabies. They have to be protected against rabies by pre-exposure rabies vaccination and regular booster doses. Methodology: The study was conducted in a biological park in Karnataka during October 2018. Animal handlers working in the various capacities at the park and having taken three primary doses of anti-rabies vaccine as pre-exposure prophylaxis were the study subjects. The booster dose of anti- rabies vaccine was administered by a team of trained vaccinators. After the vaccination all the subjects were observed for any adverse reactions for thirty minutes; subsequently the subjects were followed up for any adverse drug reactions through telephone for a period of 30 days. Results: The study included 198 subjects with a mean age of 38.1 + 12 years. Only 8 adverse reactions were reported from 8 subjects immediately following vaccination. The adverse reactions were itching 3 (1.5%) & redness 5 (2.5%); which subsided without any complications. None of the subjects developed systemic or delayed adverse reactions. Conclusion: Booster dose rabies vaccination with purified chick Embryo Cell rabies vaccine is safe in previously vaccinated animal handlers.
-
pre exposure prophylaxis against rabies in children safety of purified chick Embryo Cell rabies vaccine vaxirab n when administered by intradermal route
Human Vaccines & Immunotherapeutics, 2013Co-Authors: Haradanahalli S RavishAbstract:WHO recommends that children living in highly endemic regions be considered for pre-exposure prophylaxis with rabies vaccine, since they will be at continual, frequent or increased risk of exposure to the animal bites.1 The recommendations will come from WHO only after it has been proven by many previous scientific studies among children which have shown that pre-exposure prophylaxis using Purified Chick Embryo Cell Vaccine (PCECV) is safe and well tolerated.2-4 This has been mentioned in the discussion. The authors have not claimed/nor assumed in any part of their manuscript that they are the first to demonstrate the safety of purified chick Embryo Cell rabies vaccine when administered by intradermal route for pre-exposure prophylaxis against rabies in children.
-
evaluation of a one week intradermal regimen for rabies post exposure prophylaxis results of a randomized open label active controlled trial in healthy adult volunteers in india
Human Vaccines & Immunotherapeutics, 2012Co-Authors: M K Sudarshan, Shampur Narayan Madhusudana, Bilagumba Gangaboraiah, Doddabele Hanumanthaiah Ashwath Narayana, Ramesh Holla, Belludi Yajaman Ashwin, Haradanahalli S RavishAbstract:The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a “new one week intradermal regimen” for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick Embryo Cell (PCECV) rabies vaccine or purified veroCell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4–4-4). Blood samples were collected on Days 0, 7, 14, 28,180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and ...
-
assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route results of a metaanalysis
Human Vaccines, 2010Co-Authors: M K Sudarshan, Haradanahalli S Ravish, Bilagumba Gangaboraiah, Doddabele Hanumanthaiah Ashwath NarayanaAbstract:The metadata of 10 published studies and 3 vaccine trial reports comprising of 19 vaccine cohorts from four countries conducted over a period of 23 years (1986 - 2009) was used for metaanalysis. The vaccines studied were purified chick Embryo Cell vaccine (Rabipur, India & Germany), purified vero Cell rabies vaccine (Verorab, France; Indirab, India) & human diploid Cell vaccine (MIRV, France).The potency of these vaccines varied from 0.55 IU to 2.32 IU per intradermal dose of 0.1ml per site. The vaccines were administered to 1011subjects comprising of 19 cohorts and using five different ID regimens. The immunogenicity was measured by assays of rabies virus neutralizing antibody (RVNA) titres using rapid fluorescent focus inhibition test (RFFIT) [15 cohorts] and mouse neutralization test (MNT) [4 cohorts]. The statistical analysis of the data was done by Karl Pearson’s correlation coefficient to measure the relationship between antigenicity and immunogenicity. It was revealed that, there was no significant...
M K Sudarshan - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of a one week intradermal regimen for rabies post exposure prophylaxis results of a randomized open label active controlled trial in healthy adult volunteers in india
Human Vaccines & Immunotherapeutics, 2012Co-Authors: M K Sudarshan, Shampur Narayan Madhusudana, Bilagumba Gangaboraiah, Doddabele Hanumanthaiah Ashwath Narayana, Ramesh Holla, Belludi Yajaman Ashwin, Haradanahalli S RavishAbstract:The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a “new one week intradermal regimen” for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick Embryo Cell (PCECV) rabies vaccine or purified veroCell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4–4-4). Blood samples were collected on Days 0, 7, 14, 28,180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and ...
-
assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route results of a metaanalysis
Human Vaccines, 2010Co-Authors: M K Sudarshan, Haradanahalli S Ravish, Bilagumba Gangaboraiah, Doddabele Hanumanthaiah Ashwath NarayanaAbstract:The metadata of 10 published studies and 3 vaccine trial reports comprising of 19 vaccine cohorts from four countries conducted over a period of 23 years (1986 - 2009) was used for metaanalysis. The vaccines studied were purified chick Embryo Cell vaccine (Rabipur, India & Germany), purified vero Cell rabies vaccine (Verorab, France; Indirab, India) & human diploid Cell vaccine (MIRV, France).The potency of these vaccines varied from 0.55 IU to 2.32 IU per intradermal dose of 0.1ml per site. The vaccines were administered to 1011subjects comprising of 19 cohorts and using five different ID regimens. The immunogenicity was measured by assays of rabies virus neutralizing antibody (RVNA) titres using rapid fluorescent focus inhibition test (RFFIT) [15 cohorts] and mouse neutralization test (MNT) [4 cohorts]. The statistical analysis of the data was done by Karl Pearson’s correlation coefficient to measure the relationship between antigenicity and immunogenicity. It was revealed that, there was no significant...
-
a comparative study on the safety and immunogenicity of purified duck Embryo Cell vaccine pdev vaxirab with purified chick Embryo Cell vaccine pcec rabipur and purifed vero Cell rabies vaccine pvrv verorab
Vaccine, 2009Co-Authors: Doddabele Hanumantaiah Ashwathnarayana, Shampur Narayan Madhusudana, M K Sudarshan, Haradanahalli Shankariah Ravish, Durga Madhab Sathpathy, Ranjit Mankeshwar, Padinjaremattathil Thankappan Ullas, Tapas Ranjan Behra, G. Sampath, Manjula ShamannaAbstract:Rabies is a fatal but preventable disease. Cell culture vaccines (CCV) and purified duck Embryo vaccines (PDEV) are currently recommended by WHO for post-exposure prophylaxis. In India, a PDEV (Vaxirab) is being manufactured and is in use since 2003. In the present study, we have evaluated the safety, immunogenicity and tolerance of this vaccine with two other WHO approved CCVs, viz., purified chick Embryo Cell vaccine (PCEC, Rabipur) and purified vero Cell rabies vaccine (PVRV, Veroroab). This study was an open label, randomized phase IV comparative clinical trial. A total of 152 people bitten by dogs and other animals were recruited from 4 different centres from India. They were randomly assigned to receive one of the vaccines by Essen intramuscular regimen (52 subjects received Vaxirab and 50 each Rabipur and Verorab) and rabies immunoglobulin was also administered in all category III exposures. Their blood samples were collected on day 0 (prior to vaccination), 14, 28, 90 and 180. Side effects if any were monitored. The rabies neutralizing antibody titers in their blood samples were estimated by the rapid fluorescent focus inhibition test (RFFIT). Subjects in all three groups had neutralizing antibody titers by day 14 (>0.5 IU/mL) and geometric mean titers (GMT) observed for different vaccines on all days tested did not vary significantly (p > 0.5). Side effects observed were minimal and did not vary significantly among the groups. The results of the present study indicate that PDEV (Vaxirab) is as safe, tolerable and immunogenic as both PCEC (Rabipur) and PVRV (Verorab). Thus this vaccine can be a good alternative to WHO approved CCVs for rabies post-exposure prophylaxis.
Paul Collodi - One of the best experts on this subject based on the ideXlab platform.
-
zebrafish Embryo Cells remain pluripotent and germ line competent for multiple passages in culture
Zebrafish, 2004Co-Authors: Lianchun Fan, Jennifer Crodian, Xiangyu Liu, Annette Alestrom, Peter Alestrom, Paul CollodiAbstract:Mouse Embryonic stem (ES) Cell lines are routinely used to introduce targeted mutations into the genome, providing an efficient method to study gene function. Application of similar gene knockout techniques to other organisms has been unsuccessful due to the lack of germ-line competent ES Cell lines from non-murine species. Previously, we reported the production of zebrafish germ-line chimeras using short-term primary Embryo Cell cultures. Here we demonstrate that zebrafish Embryo Cells, maintained for several weeks and multiple passages in culture, remain pluripotent and germ-line competent. Zebrafish germ-line chimeras were generated from passage 5 and 6 cultures initiated from blastula- and gastrula-stage Embryos. In addition to the germ line, the cultured Cells contributed to multiple tissues of the host Embryo, including muscle, liver, gut, and fin. To facilitate the identification of germ-line chimeras, ES Cells expressing the green fluorescent protein (GFP) were introduced into host Embryos, and ge...
-
development of Cell cultures with competency for contributing to the zebrafish germ line
Critical Reviews in Eukaryotic Gene Expression, 2004Co-Authors: Lianchun Fan, Annette Alestrom, Peter Alestrom, Paul CollodiAbstract:The zebrafish is an established model for the genetic analysis of vertebrate development. Forward-genetic screens have generated thousands of mutations, and antisense-based methods have been used to transiently knockdown gene expression during Embryogenesis. Although these methods have made the zebrafish a valuable system for the identification and functional characterization of developmentally important genes, one deficiency of the zebrafish model is the absence of methods to introduce targeted mutations to generate knockout lines of fish. Application of gene-targeting methods has been limited in nonmurine species due to the absence of germ-line competent Embryonic stem (ES) Cell lines. Recently, progress was made in addressing this problem by the derivation of zebrafish Embryo Cell lines that remain pluripotent and germ-line competent for multiple passages in culture. Zebrafish germ-line chimeras were generated using cultures derived from Embryos at two different developmental stages, and targeted insertion of vector DNA by homologous recombination was demonstrated in both cultures. Several strategies are being used to optimize the production and identification of germ-line chimeras. The zebrafish Embryo Cell culture system should provide the basis of a gene-targeting approach that will complement other genetic strategies and improve the utility of the zebrafish model for studies of development and disease.
-
production of zebrafish germ line chimeras from Embryo Cell cultures
Proceedings of the National Academy of Sciences of the United States of America, 2001Co-Authors: Lianchun Fan, Rosemarie Ganassin, Niels C Bols, Paul CollodiAbstract:Although the zebrafish possesses many characteristics that make it a valuable model for genetic studies of vertebrate development, one deficiency of this model system is the absence of methods for Cell-mediated gene transfer and targeted gene inactivation. In mice, Embryonic stem Cell cultures are routinely used for gene transfer and provide the advantage of in vitro selection for rare events such as homologous recombination and targeted mutation. Transgenic animals possessing a mutated copy of the targeted gene are generated when the selected Cells contribute to the germ line of a chimeric Embryo. Although zebrafish Embryo Cell cultures that exhibit characteristics of Embryonic stem Cells have been described, successful contribution of the Cells to the germ-Cell lineage of a host Embryo has not been reported. In this study, we demonstrate that short-term zebrafish Embryo Cell cultures maintained in the presence of Cells from a rainbow trout spleen Cell line (RTS34st) are able to produce germ-line chimeras when introduced into a host Embryo. Messenger RNA encoding the primordial germ-Cell marker, vasa, was present for more than 30 days in Embryo Cells cocultured with RTS34st Cells or their conditioned medium and disappeared by 5 days in the absence of the spleen Cells. The RTS34st Cells also inhibited melanocyte and neuronal Cell differentiation in the Embryo Cell cultures. These results suggest that the RTS34st splenic-stromal Cell line will be a valuable tool in the development of a Cell-based gene transfer approach to targeted gene inactivation in zebrafish.